HRP20040894A2 - Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation - Google Patents

Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation

Info

Publication number
HRP20040894A2
HRP20040894A2 HR20040894A HRP20040894A HRP20040894A2 HR P20040894 A2 HRP20040894 A2 HR P20040894A2 HR 20040894 A HR20040894 A HR 20040894A HR P20040894 A HRP20040894 A HR P20040894A HR P20040894 A2 HRP20040894 A2 HR P20040894A2
Authority
HR
Croatia
Prior art keywords
preparation
lyophilizing
pharmaceutical composition
camptothecin derivative
composition producible
Prior art date
Application number
HR20040894A
Other languages
English (en)
Inventor
Ito Takahiro
Narisawa Shinji
Original Assignee
Tanabe Seiyaku Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co. Ltd. filed Critical Tanabe Seiyaku Co. Ltd.
Publication of HRP20040894A2 publication Critical patent/HRP20040894A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
HR20040894A 2002-04-16 2004-09-29 Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation HRP20040894A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16
PCT/JP2003/004745 WO2003086471A2 (fr) 2002-04-16 2003-04-15 Preparation liquide comprenant un derive de camptothecine et composition pharmaceutique pouvant etre preparee par lyophilisation de la preparation

Publications (1)

Publication Number Publication Date
HRP20040894A2 true HRP20040894A2 (en) 2005-10-31

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040894A HRP20040894A2 (en) 2002-04-16 2004-09-29 Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation

Country Status (21)

Country Link
US (1) US20050215485A1 (fr)
EP (1) EP1501549A2 (fr)
JP (1) JP3927954B2 (fr)
KR (1) KR100700963B1 (fr)
CN (1) CN100544769C (fr)
AR (1) AR039272A1 (fr)
AU (1) AU2003223120B2 (fr)
BR (1) BR0309283A (fr)
CA (1) CA2480425A1 (fr)
HR (1) HRP20040894A2 (fr)
ME (1) MEP31308A (fr)
MX (1) MXPA04010178A (fr)
MY (1) MY136696A (fr)
NO (1) NO20044964L (fr)
PL (1) PL371677A1 (fr)
RS (1) RS91204A (fr)
RU (1) RU2315623C2 (fr)
TW (1) TW200306314A (fr)
UA (1) UA77295C2 (fr)
WO (1) WO2003086471A2 (fr)
ZA (1) ZA200408008B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077370A1 (fr) * 2004-02-13 2005-08-25 Kabushiki Kaisha Yakult Honsha Préparation de solution aqueuse contenant des camptothécines
AU2005244768B2 (en) 2004-04-27 2011-06-09 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
ATE540698T1 (de) 2005-07-14 2012-01-15 Wellstat Biologics Corp Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
TWI469789B (zh) 2009-06-22 2015-01-21 Wyeth Llc 金黃色葡萄球菌抗原之免疫原性組合物
RU2531234C2 (ru) 2009-06-22 2014-10-20 ВАЙЕТ ЭлЭлСи КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
US20140161876A1 (en) * 2011-07-15 2014-06-12 Konica Minolta, Inc. Liposome-containing preparation utilizing dissolution aid, and method for producing same
WO2016103867A1 (fr) 2014-12-26 2016-06-30 日本化薬株式会社 Préparation pharmaceutique à base d'un dérivé de polymère contenant de la camptothécine
JP6735759B2 (ja) * 2015-09-03 2020-08-05 日本化薬株式会社 カンプトテシン類高分子誘導体を含有する医薬組成物
CN108135917B (zh) 2015-09-25 2021-07-09 Zy医疗 基于包含多糖-维生素缀合物的颗粒的药物制剂
WO2017150256A1 (fr) 2016-03-01 2017-09-08 日本化薬株式会社 Préparation pharmaceutique contenant un dérivé polymère à base de camptothécine
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
JPWO2023095887A1 (fr) * 2021-11-26 2023-06-01

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
BR0112417A (pt) * 2000-07-13 2003-07-01 Daiichi Seiyaku Co Composições farmacêuticas contendo composto dds
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Also Published As

Publication number Publication date
ZA200408008B (en) 2005-06-13
US20050215485A1 (en) 2005-09-29
WO2003086471A2 (fr) 2003-10-23
KR100700963B1 (ko) 2007-03-28
MY136696A (en) 2008-11-28
EP1501549A2 (fr) 2005-02-02
AR039272A1 (es) 2005-02-16
CN1646172A (zh) 2005-07-27
AU2003223120A1 (en) 2003-10-27
JP3927954B2 (ja) 2007-06-13
CA2480425A1 (fr) 2003-10-23
PL371677A1 (en) 2005-06-27
AU2003223120A2 (en) 2003-10-27
RS91204A (en) 2006-12-15
TW200306314A (en) 2003-11-16
KR20050000516A (ko) 2005-01-05
UA77295C2 (en) 2006-11-15
CN100544769C (zh) 2009-09-30
RU2315623C2 (ru) 2008-01-27
MXPA04010178A (es) 2005-06-08
BR0309283A (pt) 2005-02-15
MEP31308A (en) 2010-10-10
WO2003086471A3 (fr) 2004-04-15
NO20044964L (no) 2004-11-15
AU2003223120B2 (en) 2006-10-05
JP2005523329A (ja) 2005-08-04
RU2004133349A (ru) 2005-05-27

Similar Documents

Publication Publication Date Title
IL179207A0 (en) Pyrrole derivatives and pharmaceutical compositions containing the same
AU2003289641A1 (en) The novel coumarin-amide derivatives and its preparation, said drug composition and its use
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173627A0 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
IL177168A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
IL175214A0 (en) 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same
IL172159A0 (en) 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same
IL216734A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL178414A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL225206A (en) A derivative of multinuclear carbamoylpyridone, its pharmaceutical composition and its use
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
IL221323A0 (en) 1-methyl-1h- pyridin-2-one- phenanthridine derivatives and pharmaceutical compositions containing the same
HK1078086A1 (zh) 雜芳族五環化合物及其醫藥用途
IL183583A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
IL170758A0 (en) 7-amino-isoindolyl compounds and their pharmaceutical uses
AU2009201465A1 (en) Pharmaceutical Compositions with Improved Dissolution
IL172937A0 (en) Pyrimidine derivatives and pharmaceutical compositions containing the same
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
IL174479A (en) The derivatives of myastrin, pharmaceutical preparations containing them and their uses
IL179253A0 (en) Pyrimidine derivatives and pharmaceutical compositions containing the same
IL173628A0 (en) Aminopyridine derivatives and pharmaceutical compositions containing the same
IL174317A0 (en) Triterpene derivatives and pharmaceutical compositions containing the same
HRP20040894A2 (en) Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP

ODRP Renewal fee for the maintenance of a patent

Payment date: 20100303

Year of fee payment: 8

OBST Application withdrawn